Five-star Business Finance L (FIVESTAR.NS) traded down -7.48 % during a 24 hours period ending at 01:21 PM Central Europe on Wednesday 28th. One Five-star Business Finance L stock can currently be bought for about INR 413.7 on popular exchanges. Current supply of Five-star Business Finance L stocks is 295.2 mn. Five-star Business Finance L has a current market capitalization of INR 122.9 bn and approximately INR 869.7 mn worth of Five-star Business Finance L was traded on exchanges in the last 24 hours. Since last month end, Five-star Business Finance L has traded -19.97 % down. Simple moving average of last 200 days is at INR 482.38. The highest price of past 52 weeks was recorded at INR 666 on 10/31/2025. 52 weeks low was at INR 338.15 on 03/23/2026.
Here is how related stocks have performed in the past 24 hours:
Poly Medicure (POLYMED.NS) traded down -0.03 % and now trades at INR 1,476. Current market capitalisation for Poly Medicure is INR 146.5 bn. Poly Medicure has a current price to earnings ratio of 47.32.
Bayer Cropscience (BAYERCROP.NS) traded down -1.2 % and now trades at INR 3,282.1. Bayer Cropscience has a market capitalisation of INR 146.7 bn. Current price/earnings ratio for Bayer Cropscience is 22.03.
Avalon (AVALON.NS) traded up 7.84 % and now trades at INR 2,046.5. Avalon has a market capitalisation of INR 145.1 bn. Current price/earnings ratio for Avalon is 99.99. Avalon Technologies Limited announced that its board approved a plan to issue warrants convertible into equity shares on a preferential private‑placement basis. The proposal allows the company to raise additional capital through the sale of up to roughly 1.9 million warrants, each convertible into one fully paid share, subject to shareholder approval at a special resolution. An extra‑ordinary general meeting is scheduled for November 21, 2026, to seek member consent for the changes to the Articles of Association and the warrant issuance. The company has appointed Crisil Ratings as the monitoring agency for the use of the proceeds, in compliance with SEBI regulations. The board’s decision reflects the company’s intent to expand its capital base while providing a structured conversion window for the warrants. No immediate impact on the share price has been noted, and the market is awaiting shareholder approval.
Graphite India (GRAPHITE.NS) traded up 6.82 % and now trades at INR 735.15. Current market capitalisation for Graphite India is INR 146.8 bn. Current price/earnings ratio for Graphite India is 66.59.
Syngene (SYNGENE.NS) traded down -1.91 % and now trades at INR 410.85. Syngene has a market capitalisation of INR 147.1 bn. Syngene has a current price to earnings ratio of 68.53. Syngene International Limited reported its second‑quarter and half‑year results for the period ended September 30, 2026. The company recorded a sequential rise in revenue, driven by growth in its contract drug discovery, development and manufacturing services. Operating profitability improved, with the EBITDA margin expanding to the mid‑teens, reflecting successful cost‑optimisation and a strong contribution from its biologics and small‑molecule manufacturing units. Profit before tax after exceptional items remained positive, aided by a favourable tax position and the absence of large exceptional losses. Management highlighted the signing of a key manufacturing agreement for its Bayview biologics facility in the United States, underscoring a strategic push to broaden global supply capabilities. Board approval of the unaudited financial statements was announced, and the company disclosed a management transition that saw two senior executives move to non‑senior roles and a chief financial officer departing.